Table 5.
Human cancer cell growth inhibitory activity GI50 (nM) of 9 in NCI 60 cell line panel.
| Panel/Cell line | GI50 (nM) | Panel/Cell line | GI50 (nM) | Panel/Cell line | GI50 (nM) | Panel/Cell line | GI50 (nM) |
|---|---|---|---|---|---|---|---|
| Leukemia | Colon Cancer | Melanoma | Renal Cancer | ||||
| CCRF-CEM | 9.96 | COLO 205 | 9.78 | LOX IMVI | 8.53 | 786-0 | 13.23 |
| HL-60 (TB) | 11.23 | HCC-2998 | 23.56 | MALME-3M | 12.07 | A498 | 13.42 |
| K-562 | 6.46 | HCT-116 | 9.07 | M14 | 10.56 | ACHN | 8.40 |
| MOLT-4 | 19.85 | HCT-15 | 5.14 | MDA-MB-435 | 3.90 | CAKI-1 | 15.72 |
| RPMI-8226 | 15.29 | HT29 | 7.60 | SK-MEL-2 | 20.97 | RXF 393 | 8.75 |
| SR | 9.64 | KM12 | 10.76 | SK-MEL-28 | 17.04 | SN12C | 15.76 |
| NSCLC | SW-620 | 6.67 | SK-MEL-5 | 14.58 | TK-10 | 16.31 | |
| A549/ATCC | 12.67 | CNS Cancer | UACC-257 | 22.69 | UO-31 | 10.01 | |
| EKVX | 15.47 | SF-268 | 12.17 | UACC-62 | 15.90 | ||
| HOP-62 | 15.41 | SF-295 | 11.43 | Ovarian cancer | Breast Cancer | ||
| HOP-92 | 16.03 | SF-539 | 8.76 | IGROVI | 13.30 | MCF7 | 10.81 |
| NCI-H226 | 9.49 | SNB-19 | 13.88 | OVCAR-3 | 6.37 | MDA-MB-231/ATCC | 14.29 |
| NCI-H23 | 11.87 | SNB-75 | 10.81 | OVCAR-4 | 12.93 | HS 578T | 11.19 |
| NCI-H322M | 14.09 | U251 | 7.97 | OVCAR-5 | 11.76 | BT-549 | 24.12 |
| NCI-H460 | 4.52 | Prostate Cancer | OVCAR-8 | 14.69 | T-47D | 16.44 | |
| NCI-H522 | 14.43 | PC-3 | 10.73 | NCI/ADR-RES | 8.24 | MDA-MB-468 | 9.09 |
| DU-145 | 8.89 | SK-OV-3 | 13.93 |